Figure 3.

In vivo antitumor effects of localized delivery of TBD‐3C in KPC and Panc02 tumor‐bearing mice. A) Schematic illustration of TBD‐3C‐based PDT‐arousing pyroptosis to inhibit tumor growth. C57 mice were subcutaneously inoculated with 5 × 10⁵ KPC cells or 2 × 10⁵ Panc02 cells on day 7. PBS or TBD‐3C was then intratumorally injected on day 3 and under white light irradiation (40 mW cm⁻², 10 min) for 24 h after injection. B) The tumor weights and C) tumor growth curves of various treatment groups. D) Western blotting analysis of HMGB1, CRT, GSDMD‐FL, and GSDMD‐N in tumor tissue after treatments (n = 3). E) Quantitative analysis of ATP in tumor tissue after treatments (n = 5). F) Pathology studies show α‐SMA, Ki‐67, and CD8 expression in the mice in different groups in the KPC model. The bars represent 50 µm. G) Ki‐67 and CD8 positivity analyses in the KPC model (n = 5). Flow cytometry quantification of H) CD8, I) CD69, J) CD103, and K) PD‐1 expression on intratumoral infiltration CTLs with TBD‐3C photodynamic treatment in the KPC model. Data are presented as the mean ± SD. Statistical analysis was performed by Student's t‐test (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001).